Public BoD papers 28.04.22

Short title

Objective

Lead Investigator Prof Rob Bristow

Domain

HYPROGEN To investigate the biology of

Clinical Oncology Radiotherapy related research Medical Oncology Lymphoma

resistance to treatment in patients with advanced prostate cancer Funded by Prostate Cancer UK

DETECTION Application of liquid biopsies to detect and treat recurrence after surgery using immunotherapy Funded by Cancer Research UK

Prof Paul Lorigan Clinical Fellow Dr Rebecca Lee Dr Gerben Borst (AIP funded)

POBIG

Funded by Cancer Research UK RADNET Grant Designed to test radiotherapy combined with surgery for treatment of gliobastoma Open nationally to patients with any type of cancer and of any age, including children. Liquid biopsies will be used to sequence cancer DNA in the bloodstream

Radiotherapy Related Research

TARGET National

Dr Matt Krebs

Medical Oncology Experimental Cancer Medicine Team

Table 7 : Selected Publications of Research Selected publications of real world evidence / observational outcomes research (First author, journal): • Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during Covid-19 reveals features associated with outcome (Dr Rebecca Lee, ESMO Open). • Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies (Dr Tim Cooksley, The Journal of Emergency Medicine) • Enrolment of older adults with cancer in early phase trials (Dr Fabio Gomes, Age and Ageing) • A novel model and infrastructure for clinical outcomes data collection and their systematic evaluation for UK patients receiving proton beam therapy (Dr Ed Smith, Clinical Oncology) • Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33 year experience in 14,311 women (Prof Gareth Evans, Breast Cancer Research and Treatment) • Long term outcomes for patients with peritoneal acellular mucinosis secondary to low grade appendiceal mucinous neoplasms (T Evans, European Journal of Surgical Oncology) • Evaluation of safety and effectiveness of prostate-specific antigen (PSA) monitoring in primary care after discharge from hospital-based follow-up following prostate cancer treatment (S Taylor, European Journal of Cancer Care) Selected publications of biobank research (First author, journal): • Early adaptation of colorectal cancer cells to the peritoneal cavity is associated with activation of stem-ness programs and local inflammation (Jorge Burriuso, Clinical Cancer Research) • Helen Adderley, The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma (Dr Helen Adderley, Oral Oncology) Selected publications of clinical trials (First author, journal): • Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta- analysis of the BC2001 and BCON trials (Prof Ananya Choudhury, Lancet Oncology) • Objective Responses to first line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. (Robert Morgan, Lancet Oncology) • PROCLAIM-CX-072 FIH, dose finding - advanced solid tumours (Prof Fiona Thistlethwaite, Journal for Immunotherapy of Cancer) • A Phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08) (Mairead McNamara, The Oncologist) • Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a

68